David Donabedian
Board of Directors @ KALA BIO
Boston, United States
David Donabedian is a Series A investor at KALA BIO in Boston focused on Biotechnology and Life Science. David Donabedian is based out of Boston, Massachusetts and is the Co-Founder and Senior Advisor of Newleos Therapeutics. David previously worked at DEM Biopharma as a Co-founder, Start-up CEO and Sr. Advisor. David Donabedian attended the University of Massachusetts, Lowell.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries David Donabedian invests in
Stages David Donabedian invests in
Countries David Donabedian invests in
Investment Focus
Industry
- Biotechnology 2 (100%)
- Life Science 1 (50%)
- Neuroscience 1 (50%)
- Pharmaceutical 1 (50%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Newleos Therapeutics
|
Newleos Therapeutics is a biotech startup dedicated to producing safer and more effective neuroscience medicines. | $93.5M / Series A / Feb 13, 2025 | |
DEM BioPharma
|
DEM BioPharma is an immuno-oncology company that is working to eradicate cancer by targeting novel innate immune system checkpoints. | $70M / Series A / Jun 23, 2022 |
Co-Investors
About KALA BIO
Kala Pharmaceuticals is developing novel treatments for diseases that affect mucosal tissues. The company's proprietary mucus penetrating particle technology dramatically improves drug distribution and pharmacokinetics by uniformly coating the mucosal surface with biocompatible, drug-loaded particles. Kala's formulations achieve high,sustained local drug concentrations with reduced systemic exposure and are delivered in a patient-friendly format. The company's research efforts have demonstrated successful in vivo proof-of-concept in mucosal organs such as the respiratory tract, eye, and cervicovaginal tract, enabling diverse product opportunities that target significant clinical unmet need. Kala is focused on advancing an internal pipeline of products through human proof-of-concept while establishing R&D collaborations with select partners to improve products in their pipelines.
KALA BIO Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Bennett Shapiro
Scientific Advisors
|
|||
|
David Donabedian
Board of Directors
|
|||
David Donabedian, PhD
Board of Directors
|
|||
Andrea Franz
Chief Financial Officer
|
|||
Gregory D. Perry
Audit Committee Chairman
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does David Donabedian invest in?
David Donabedian invests primarily in Biotechnology, Life Science and Neuroscience startups, most often at Series A stage. Most of the 2 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did David Donabedian last invest?
The most recent investment recorded for David Donabedian closed in Feb 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
